553 related articles for article (PubMed ID: 33455920)
41. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases.
Romero-Bogado L; Steiner M; Thuissard Vasallo IJ; Andreu Vázquez C; Navío T; Muñoz-Fernández S;
Med Clin (Barc); 2024 May; 162(10):470-476. PubMed ID: 38418311
[TBL] [Abstract][Full Text] [Related]
42. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.
Costagliola G; Spada E; Consolini R
Pediatr Rheumatol Online J; 2021 May; 19(1):68. PubMed ID: 33947420
[TBL] [Abstract][Full Text] [Related]
43. Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
Kardeş S; Kuzu AS; Pakhchanian H; Raiker R; Karagülle M
Clin Rheumatol; 2021 May; 40(5):2047-2055. PubMed ID: 33130946
[TBL] [Abstract][Full Text] [Related]
44. Trends in severe outcomes in SARS-CoV-2-positive hospitalized patients with rheumatic diseases: a monocentric observational and case-control study in northern Italy.
Ughi N; Bernasconi DP; Gagliardi C; Del Gaudio F; Dicuonzo A; Maloberti A; Giannattasio C; Rossetti C; Valsecchi MG; Epis OM
Reumatismo; 2023 Jul; 75(2):. PubMed ID: 37462130
[TBL] [Abstract][Full Text] [Related]
45. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
46. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry.
Membrive-Jiménez C; Sánchez-Piedra C; Martínez-González O; García-González J; Expósito-Pérez L; Bohórquez-Heras C; Campos-Fernández C; Sanchez-Alonso F; Cáliz-Cáliz R; Castrejón-Fernández I
Reumatol Clin (Engl Ed); 2023 Nov; 19(9):500-506. PubMed ID: 37945183
[TBL] [Abstract][Full Text] [Related]
47. Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study.
Nuñez DF; Leon L; Garcia AM; Arce JIC; Mucientes A; Gutierrez-Fernandez B; Rodriguez L; Cristóbal IPS; Álvarez P; Prada CM; Abasolo L
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090296. PubMed ID: 35510167
[TBL] [Abstract][Full Text] [Related]
48. Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.
Sahebari M; Mirfeizi Z; Hashemzadeh K; Salavati Nik E; Gholampoor Shamkani N
Arch Bone Jt Surg; 2022 Nov; 10(11):964-968. PubMed ID: 36561225
[TBL] [Abstract][Full Text] [Related]
49. Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases.
Kawano Y; Wang X; Patel NJ; Qian G; Kowalski E; Bade KJ; Vanni KMM; Jonsson AH; Williams ZK; Cook CE; Srivatsan S; Wallace ZS; Sparks JA
J Rheumatol; 2024 Mar; 51(3):305-312. PubMed ID: 37839812
[TBL] [Abstract][Full Text] [Related]
50. Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand.
Brooks J; Montgomery A; Dalbeth N; Sapsford M; Ngan Kee R; Cooper A; Quincey V; Bhana S; Gore-Massy M; Hausmann J; Liew J; Machado PM; Sufka P; Sirotich E; Robinson P; Wallace Z; Yazdany J; Grainger R
Lancet Reg Health West Pac; 2023 Sep; 38():100843. PubMed ID: 37520279
[TBL] [Abstract][Full Text] [Related]
51. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy.
Ekin A; Coskun BN; Dalkilic E; Pehlivan Y
Ir J Med Sci; 2023 Aug; 192(4):1959-1973. PubMed ID: 36258064
[TBL] [Abstract][Full Text] [Related]
52. The role of immunomodulatory medications in the treatment of COVID-19.
Sattui SE; Crow MK; Navarro-Millán I
Curr Opin Rheumatol; 2021 Sep; 33(5):431-445. PubMed ID: 34397605
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.
Pascual Pareja JF; García-Caballero R; Soler Rangel L; Vázquez-Ronda MA; Roa Franco S; Navarro Jiménez G; Moreno Palanco MA; González-Ruano P; López-Menchaca R; Ruíz-Seco P; Pagán Muñoz B; Gómez Gómez A; Pérez-Monte B; Fuerte Martínez R; Valle López JL; Muñoz Blanco A; Rábago Lorite I; Martínez Martín P; Serralta San Martín G; Gómez-Cerezo JF;
Med Clin (Barc); 2021 Mar; 156(5):221-228. PubMed ID: 33380371
[TBL] [Abstract][Full Text] [Related]
54. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
Lancet Rheumatol; 2023 Mar; 5(3):e139-e150. PubMed ID: 36844970
[TBL] [Abstract][Full Text] [Related]
55. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Manrique-Rodríguez S; Lobato-Matilla E; García-Moreno F; Olmedo M; Correa-Rocha R; Valerio M; Aldámiz-Echevarria T; Machado M; Sancho-Gonzalez M; Lopez-Bernaldo-de-Quirós JC; Ruiz-Briones P; Romero-Jiménez R; Sarobe-González C; Gimenez-Manzorro A; Collado-Borrell R; Fernandez-Llamazares CM; Revuelta-Herrero JL; Somoza-Fernandez B; Garcia-Sanchez S; Taladriz-Sender I; Bouza E; Herranz A; Muñoz P; Sanjurjo M
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):249-260. PubMed ID: 33499687
[No Abstract] [Full Text] [Related]
56. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L
Immunol Lett; 2020 Dec; 228():122-128. PubMed ID: 33161002
[TBL] [Abstract][Full Text] [Related]
57. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
Meira F; Albiach L; Carbonell C; Martín-Oterino JA; Martín-Ordiales M; Linares L; Macaya I; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Morata L; Puerta-Alcalde P; Rico V; Letona L; Cózar-Llistó A; Dueñas G; Solá M; Torres B; Rojas J; Moreno A; Moreno-García E; Torres M; Martínez JA; Soriano A; García F
Rev Esp Quimioter; 2021 Aug; 34(4):337-341. PubMed ID: 33982984
[TBL] [Abstract][Full Text] [Related]
58. Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020: A Systematic Review.
Schlegel M; Bachmann S
Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674242
[TBL] [Abstract][Full Text] [Related]
59. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.
Lima LM; Aurilio RB; Fonseca AR; Parente AAAI; Sant'Anna MFBP; Sant'Anna CC
Rev Paul Pediatr; 2023; 42():e2022084. PubMed ID: 37436237
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Marchetti M; Salmanton-García J; El-Ashwah S; Verga L; Itri F; Ráčil Z; Dávila-Valls J; Martín-Pérez S; Van Doesum J; Passamonti F; Abu-Zeinah G; Farina F; López-García A; Dragonetti G; Cattaneo C; Gomes Da Silva M; Bilgin YM; Žák P; Petzer V; Glenthøj A; Espigado I; Buquicchio C; Bonuomo V; Prezioso L; Meers S; Duarte R; Bergantim R; Jaksic O; Čolović N; Blennow O; Cernan M; Schönlein M; Samarkos M; Mitra ME; Magliano G; Maertens J; Ledoux MP; Jiménez M; Demirkan F; Collins GP; Cabirta A; Gräfe SK; Nordlander A; Wolf D; Arellano E; Cordoba R; Hanakova M; Zambrotta GPM; Nunes Rodrigues R; Limberti G; Marchesi F; Cornely OA; Pagano L
Ther Adv Hematol; 2023; 14():20406207231154706. PubMed ID: 36923264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
